Cargando…
MMP-14 (MT1-MMP) Is a Biomarker of Surgical Outcome and a Potential Mediator of Hearing Loss in Patients With Vestibular Schwannomas
Improved biomarkers are needed for vestibular schwannoma (VS), the most common tumor of the cerebellopontine angle, as existing clinical biomarkers have poor predictive value. Factors such as tumor size or growth rate do not shed light on the pathophysiology of associated sensorineural hearing loss...
Autores principales: | Ren, Yin, Hyakusoku, Hiroshi, Sagers, Jessica E., Landegger, Lukas D., Welling, D. Bradley, Stankovic, Konstantina M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424165/ https://www.ncbi.nlm.nih.gov/pubmed/32848608 http://dx.doi.org/10.3389/fncel.2020.00191 |
Ejemplares similares
-
Identification of Immune-Related Candidate Biomarkers in Plasma of Patients with Sporadic Vestibular Schwannoma: Candidate Plasma Biomarkers in Vestibular Schwannoma
por: Vasilijic, Sasa, et al.
Publicado: (2023) -
Identification of immune-related candidate biomarkers in plasma of patients with sporadic vestibular schwannoma
por: Vasilijic, Sasa, et al.
Publicado: (2023) -
Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas
por: Ren, Yin, et al.
Publicado: (2017) -
Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma
por: Sagers, Jessica E., et al.
Publicado: (2018) -
Publisher Correction: Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma
por: Sagers, Jessica E., et al.
Publicado: (2018)